Oncolytics Biotech is trading at $0.42, up 10.28%, following new translational data from its ongoing anal-cancer study.
- On November 4, the company announced the data, presented at the SITC 2026 Annual Meeting, reporting increased immune-activation biomarkers and expansion of tumor-infiltrating and HPV-16-specific T-cell clones.
- The release preceded the reported price move and is a company-specific catalyst; the broader biotech rally, with XBI up 2.13%, may also support shares. No current volume figure was verified.